Pfizer experimental sickle cell drug fails phase 3 trial
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'
In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality. What Happened: Cramer made a case last week, asserting that the current market conditions are far removed from the dotcom bubble burst of the late 90s. He emphasized that despite the froth, today's market is more rational. Cramer drew attention to the irrationality in recent IPOs like Circle, Figma, and Bullish, which have witnessed significant gains since their launch. On CNBC, he also noted Oklo Inc., a firm with ambitions to construct a compact nuclear reactor powered by nuclear waste, whose stock has surged 247% year-to-date. 'Flying cars, supercharged crypto ETFs, secretive companies that consult in magical ways, all irrational. I could go on and on,' Cramer said. 'Is the widespread irrationality a reason to sell down your positions in perfectly rational stocks? Absolutely not.' Also Read: Jim Cramer Has Blunt Message for Fed Chair Powell After July Job Numbers Tanked On the other hand, Cramer pointed to Amazon Inc. (NASDAQ:AMZN) and Eli Lilly and Company (NYSE:LLY) as instances of rationality. Amazon's stock climbed by 3% after the introduction of same-day fresh food delivery in over 1,000 U.S. cities and towns. Eli Lilly's stock also experienced a boost when a team from the pharmaceutical company's management and board of directors purchased stock on the open market. 'Sure, there's froth, but there are also perfectly legitimate moves in the stocks of great companies. I am calling this the year of magical thinking, but the truth is you can't get the runs in the good ones without the runs in the bad ones,' Cramer added. Read Next Short Seller Slams Jim Cramer Over Palantir, Accuses Him Of Hyping 'High-Multiple, Hype-Driven Narrative' Image: Shutterstock/katz Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? (AMZN): Free Stock Analysis Report ELI LILLY (LLY): Free Stock Analysis Report This article Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
Key Points Pfizer's revenue rose by 10% last quarter, exceeding market expectations. The drugmaker has been cutting costs, which has paid off at the bottom line. However, the industry is feeling government pressure to bring drug prices down. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine resulted in the business posting record sales and profits in 2022. But then, as things went back to normal and demand diminished for its vaccine, so too did interest in Pfizer's stock. What's startling, however, is the stock hasn't simply gone back to the levels it was at back before the pandemic -- it has been on a full-blown crash. Since 2023, the healthcare stock has lost more than half of its value. This year, it's reached levels it hasn't seen in 13 years. It seems like a steal of a deal. Except, no one is in a rush to buy Pfizer's stock. Investors are concerned about what lies ahead for the business and there are many question marks about its future growth. Recently, the company released some positive earnings numbers. Could they mark a turning point for this struggling stock, and could now be a good time to invest in Pfizer? Pfizer posts strong Q2 numbers and boosts guidance On Aug. 5, Pfizer released its second-quarter earnings for 2025. Revenue for the June quarter totaled $14.7 billion, rising 10% year over year. And it easily came in above analyst estimates of $13.6 billion. On the bottom line, its adjusted earnings per share (EPS) was $0.78, also smashing expectations of $0.58. It also raised its guidance, now projecting adjusted EPS between $2.90 and $3.10 for the full year (versus its previous guidance of $2.80 to $3.00). With a result like that, you might have expected shares of Pfizer to take off. Not only did it beat expectations, it performed the highly coveted beat-and-raise combo. And yet, the stock has barely moved since releasing its quarterly numbers. The stock is now being weighed down by other factors Pfizer can't catch a break. Its strong earnings performance comes at a time when the U.S. government is threatening tariffs on imported pharmaceuticals and is trying to get pharma companies to reduce drug prices. This doesn't bode well for the company, as these types of developments could lead to shrinking numbers on both its top and bottom lines. The good news is that this isn't a Pfizer-specific problem. These are industry headwinds weighing down healthcare stocks as a whole. The Health Care Select Sector SPDR Fund has declined by 13% in the past 12 months, which is similar to how Pfizer has performed over that stretch. The bad news, however, is that there is so much uncertainty about how all these factors might play out, how they might impact Pfizer's financials, and how long they may last. With so many question marks, it's easy to see why investors may be looking elsewhere to invest. Pfizer may be an ideal buy-and-wait stock I don't know how government policies will play out, or how they'll affect Pfizer's business in particular. But I am confident that in the long run, policies will be put in place to incentivize pharma companies to develop life-saving drugs and treatments, not deter them. That's why regardless of what happens in the short term with respect to government actions, I don't believe that in the long run they will weigh down and impede Pfizer and other top healthcare businesses, which continually invest in their growth and the development of new drugs. It may take a while before optimism returns to the healthcare sector, and Pfizer's stock may not end up rallying in the days or weeks ahead. But with the business's cost-cutting efforts paying off and the company exhibiting a lot of growth with the potential for even more in the long run, Pfizer may be one of the best stocks to put in your portfolio right now and simply forget about. Plus, with a dividend yield of 7%, there's plenty of incentive to remain patient with the stock. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Chamath Palihapitiya Once Disclosed He Was A Warren Buffett Disciple, But Disagreed With The Investing Legend's 'Wrong, Outdated' Views On Bitcoin
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Venture capitalist Chamath Palihapitiya has long been a staunch advocate of Bitcoin (CRYPTO: BTC) and did not mince words when criticizing legendary investor Warren Buffett's scathing remarks about the asset. Palihapitya Defends Crypto Against Buffett's Criticism During a CNBC interview in 2020, Palihapitiya said that Buffett is "completely wrong and outdated" about Bitcoin and cryptocurrency. For background, Buffett said in an earlier interview that cryptocurrencies have no value and he will never wager his money on them. Palihapitiya then defined Bitcoin as the only 'uncorrelated hedge' in the world and urged putting 1% of one's portfolio to the apex cryptocurrency. Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — It's Okay To Have Biases, Says Palihapitiya This wasn't the first time Palihapitiya disagreed with Buffett on cryptocurrency. In a May 2018 interview with CNBC, he said, 'It's really unfair to not understand something and then disparage it,' in response to Buffett's remark that Bitcoin is "creating nothing." "I think we have to acknowledge that we all have biases," Palihapitiya added. Despite his criticism, he called Buffett an 'exceptional' person and claimed to be a 'disciple' of the renowned investor. On the date of the interview, Bitcoin closed at $9,325.18 apiece. As of this writing, it is exchanging hands at $121,809.56, marking a massive 1206.24% increase. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo Courtesy: Kathy Hutchins On Shutterstock This article Chamath Palihapitiya Once Disclosed He Was A Warren Buffett Disciple, But Disagreed With The Investing Legend's 'Wrong, Outdated' Views On Bitcoin originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
